BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharma Journalist - ECPv6.16.1//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-ORIGINAL-URL:https://www.pharmajournalist.com
X-WR-CALDESC:Events for Pharma Journalist
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Asia/Kolkata
BEGIN:STANDARD
TZOFFSETFROM:+0530
TZOFFSETTO:+0530
TZNAME:IST
DTSTART:20220101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20240123
DTEND;VALUE=DATE:20240126
DTSTAMP:20260515T042055
CREATED:20230927T095451Z
LAST-MODIFIED:20230929T103625Z
UID:37864-1705968000-1706227199@www.pharmajournalist.com
SUMMARY:Gene Therapy Regulatory Affairs Summit
DESCRIPTION:With 2023 welcoming newly FDA-approved gene therapies from BioMarin\, Krystal Biotech and Sarepta Therapeutics\, many more treatments are hot on their heels for approval\, investment is pouring into developing gene therapies and the role of regulatory affairs has never been more important. \nAs the first ever regulatory affairs forum wholly dedicated to gene therapy\, this meeting uniquely unites regulatory bodies and the leading regulatory personnel across big pharma and innovative biotech to discuss the hottest topics\, identify industry bottlenecks and offer actionable insights. \nJoin 80+ industry leaders from 4D Molecular Therapeutics\, Advanced Cell & Gene Therapy\, Adverum Biotechnologies\, Astrazeneca\, Bridge Bio\, Health Canada\, Omega Therapeutics\, Opus Genetics\, Regeneron Pharmaceuticals\, Sangamo Therapeutics\, Solid Biosciences\, Spark Therapeutics\, Ultragenyx Pharmaceutical\, and more… \nBy attending this summit\, you will get a chance to: \n\nUnderstand the nuanced differences and the route to harmonization in global regulation across the EMA\, MHRA\, FDA & Health Canada\nHone your regulatory intelligence\, understand how to use biomarkers as surrogate endpoints and perfect clinical trial strategy for regulatory success\nExplore the next steps for specific technologies beyond AAV and novel regulatory route\nHear from the regulators in the Health Canada and the FDA to have your queries clarified\n\nOvercome your CMC hurdles to prove the efficacy\, purity & comparability of your compound to avoid later setbacks in poor manufacturing preparation \nDon’t miss out on this unrivalled opportunity to inform your trial design\, perfect your CMC approach and supercharge your global submission strategy for regulatory success. \nDownload the full agenda here to see our full speaker faculty\, 3-day agenda and audience breakdown: https://ter.li/sgkcr9
URL:https://www.pharmajournalist.com/event/gene-therapy-regulatory-affairs-summit/
LOCATION:Boston Park Plaza\, 50 Park Plaza\, Boston\, MA\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20240109
DTEND;VALUE=DATE:20240112
DTSTAMP:20260515T042055
CREATED:20231026T085211Z
LAST-MODIFIED:20231026T085354Z
UID:38024-1704758400-1705017599@www.pharmajournalist.com
SUMMARY:Pre-Filled Syringes and Injectable Drug Devices Europe
DESCRIPTION:SAE Media Group’s 16th Annual Pre-Filled Syringes and Injectable Drug Devices Conference will return to London in January 2024 to unite leaders from the industry and bring you the latest advances in the combination product drug delivery space. \n \nYear on year\, the field of injectable drug delivery has witnessed remarkable progress\, marked by advancements in device technology\, including smart devices and those designed for large volume drug administration. There has been a shift towards enhancing the patient experience through innovative device design. Moreover\, the industry is now moving towards a circular approach for environmental sustainability\, incorporating it into device manufacturing and design\, as well as device usage. The upcoming conference aims to tackle pressing industry challenges by exploring them through real-world case studies and valuable insights while also considering opportunities for the future. \nAs part of SAE’s leading Injectable Drug Delivery Series\, the 3-day event will comprise of a pre-conference focus day exploring the advances in PFS design for enhanced drug delivery proceeded by a two-day main conference comprising of morning keynote plenaries and parallel afternoon topic streams as detailed below addressing the industry’s hottest topics: \n\nDevice Innovations for Large Volume and Highly Viscous Drug Delivery\nSustainability by Design and Material Selection\nPrimary Packaging Development\nDigital Integration for Connected Devices\n\nThis event will not only bring you key insights needed to expand and enhance your injectable device portfolio but will also give you the opportunity to network with key players throughout the industry. We hope to welcome you to this must attend event in January 2024! \nBenefits of attending:  \n\nEngage with pharma\, biotech and device developers on the latest trends within the pre-filled syringe and injectable device market\nHear about new technological advances in the delivery of large volume drugs and novel drug products\nUnderstand the latest regulatory requirements from experts surrounding medical devices and digital health\nGain insight into how big pharma is incorporating sustainable approaches into drug device design\nDelve into the growing potential of digital health to improve patient experience and treatment\n\nExplore key considerations for material components for the development of primary packaging \nTo know more visit: www.pre-filled-syringes.com/PharmaJournalist-WL
URL:https://www.pharmajournalist.com/event/pre-filled-syringes-and-injectable-drug-devices-europe-2024/
LOCATION:LEONARDO ROYAL HOTEL LONDON TOWER BRIDGE\, 45 Prescot Street\, London\, E1 8GP\, United Kingdom
ORGANIZER;CN="SAE Media Group":MAILTO:events@saemediagroup.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20231213
DTEND;VALUE=DATE:20231215
DTSTAMP:20260515T042055
CREATED:20230907T095249Z
LAST-MODIFIED:20230907T095249Z
UID:37740-1702425600-1702598399@www.pharmajournalist.com
SUMMARY:Gene Therapy Process Development Summit
DESCRIPTION:The inaugural Gene Therapy Process Development Summit is a must-attend to discover the latest insights to bridge the gap between R&D and process development\, ensuring that high-quality gene therapies are manufactured repeatably\, at scale\, and in a cost-effective manner. \nJoin us in Philadelphia to discover and learn the latest insights through case study presentations\, informative panel discussions\, and deep-dive workshops from Ultragenyx\, REGENXBIO\, Janssen\, Amgen\, Astellas Gene Therapies\, and many more! \nWhether you are looking to improve your platform processes or shorten development timelines this summit will be a unique opportunity to meet and network with peers to discuss successes and challenges in your process development journeys. \nJoin your peers to: \n\nLearn how to achieve the ideal complex size with Meira GTx by using automation and process analytical tools to optimize transient transfection leading to enhanced efficiency\, time saving and scale-up insights\nDeep dive into enhancing the Pinnacle PCL Platform 2000L batch process with Ultragenyx to increase yield\, improve product quality and reduce time-to-clinic\nExamine case study results with Astellas Gene Therapies and explore the optimization techniques to cut costs and streamline tech transfer and scale-up times\nExplore the design principles for creating robust AAV producer cell lines to yield a stable and consistent AAV production to optimize AAV vector generation to improve your platform processes with Lacerta and REGENXBIO\nUnpick the ever-changing\, complex regulations surrounding the world of gene therapy in a detailed workshop that doubles down on development strategies that are adaptable to the challenges by gene therapy to prevent regulatory roadblocks when trying to get drugs to clinic\n\nDownload the full agenda here to see our full speaker faculty\, 2-day agenda and audience breakdown: https://ter.li/nxp0nz
URL:https://www.pharmajournalist.com/event/gene-therapy-process-development-summit/
LOCATION:Le Meridien Philadelphia\, 1421 Arch Street\, Philadelphia\, PA\, 19102\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20231212
DTEND;VALUE=DATE:20231215
DTSTAMP:20260515T042055
CREATED:20231031T110228Z
LAST-MODIFIED:20231031T110322Z
UID:38052-1702339200-1702598399@www.pharmajournalist.com
SUMMARY:8th Oncolytic Virotherapy Summit 2023
DESCRIPTION:Following recent struggles in the industry\, the leading annual 8th Oncolytic Virotherapy Summit returns to Boston\, MA in December (12-14)\, as the industry’s definitive\, and most comprehensive forum. Bringing you 29+ world-class speakers\, 10+ hours of networking\, 2-panel discussions\, 1 pre-conference focus day & more. This event will be showcasing brand-new pivotal data to ensure a pathway of success for regulatory approval of OV drugs. \n3 days of carefully curated sessions will gather 100+ OV trailblazers across sessions spanning Early Discovery\, Translation\, Clinical Development\, Chemistry\, Manufacturing & Controls (CMC)\, and Regulations to overcome the industry’s largest and critical bottlenecks. Here is just a snapshot of our world-class speaker line-up who will be showcasing their expertise and critical updates: \n\nRichard Dambra\, Scientist\, Viral Platforms\, Boehringer Ingelheim\nFrancesca Barone\, CSO\, Candel Therapeutics\nMichael Franti\, Director\, Viral Platform Drug Metabolism & Pharmacokinetics\, Boehringer Ingelheim\nPaul Hallenbeck\, Chief Scientific Officer\, Seneca Therapeutics\nTalia Biran\, President Clinical Development Operations\, Oncolys\n\nThis year’s edition brings highly promising content such as the exclusive Innovation Showcase\, a whole day dedicated to Clinical Design & Manufacturing Strategies and a must-attend Investor Panel from experts in Biopharma. \nAs the only and longest established end-to-end OV-focused conference\, this is a crucial date in the industry calendar you cannot afford to miss. \nTo know more visit: https://ter.li/1ag3m6
URL:https://www.pharmajournalist.com/event/8th-oncolytic-virotherapy-summit-2023/
LOCATION:Hilton Boston Back Bay\, 40 Dalton St\, Boston\, MA\, 02115\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20231212
DTEND;VALUE=DATE:20231215
DTSTAMP:20260515T042055
CREATED:20231018T112219Z
LAST-MODIFIED:20231018T112219Z
UID:37976-1702339200-1702598399@www.pharmajournalist.com
SUMMARY:Health Economics & Outcomes Research Summit
DESCRIPTION:The Health Economics & Outcomes Research Summit is a focused intimate gathering of HEOR professionals\, moving past basic introductions to advanced tactical and strategic conversations best leveraging innovative methods to demonstrate the value proposition of new drugs to secure formulary and market access. \nHear cutting-edge case studies into evidence generation\, modeling and real-world evidence across oncology\, neurology\, cardiovascular\, rare diseases\, and beyond. Explore how leading pharma and pioneering biotechs are navigating this changing landscape including:  \n\nAdapting value assessments for evolving reimbursement requirements\nAdjusting to price control mechanisms implemented by the Inflation Reduction Act\nLeveraging advances AI to revolutionize data-driven decision-making \n\n\nJoin this gathering of HEOR experts and gain strategic and commercial market intelligence by exploring how thought leaders are redefining a robust strategy to demonstrate the clinical effectiveness\, safety\, and cost-effectiveness of new drugs\, don’t miss out on your opportunity to fortify a resilient decision-making framework.  \nTo know more visit: https://bit.ly/3PTp5M4
URL:https://www.pharmajournalist.com/event/health-economics-outcomes-research-summit/
LOCATION:Wyndham Philadelphia Historic District\, 400 Arch Street\, Philadelphia\, PA\, 19106\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20231212
DTEND;VALUE=DATE:20231215
DTSTAMP:20260515T042055
CREATED:20230914T091348Z
LAST-MODIFIED:20230914T091348Z
UID:37788-1702339200-1702598399@www.pharmajournalist.com
SUMMARY:6th RNA-Targeted Drug Discovery & Development Summit
DESCRIPTION:200+ Attendees | 33+ World-Class Speakers | 23+ Data Driven Case Studies \nReturning to Boston this December for its 6th year\, the RNA-Targeted Drug Discovery & Development Summit is the only industry-dedicated forum solely focused on small molecules targeting RNA\, with a core focus on improving selectivity and specificity to enable safe and effective drugs into the clinic. \nView the program here: https://ter.li/xq2eye \n2023 has seen advances in artificial intelligence\, screening tools and progression into the clinic\, coupled with numerous strategic collaborations and investments into early discovery. \nBringing together 33+ experts presenting the latest data and case studies straight from the lab\, alongside senior decision makers discussing key breakthroughs and strategy\, this year’s meeting is a must-attend if you are looking to turbocharge discovery and development of small molecules targeting RNA. \nRegister here: https://ter.li/r67ejq
URL:https://www.pharmajournalist.com/event/6th-rna-targeted-drug-discovery-development-summit/
LOCATION:Hilton Boston Back Bay\, 40 Dalton St\, Boston\, MA\, 02115\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20231212
DTEND;VALUE=DATE:20231215
DTSTAMP:20260515T042055
CREATED:20230908T111459Z
LAST-MODIFIED:20230908T111459Z
UID:37759-1702339200-1702598399@www.pharmajournalist.com
SUMMARY:Covalent Drug Discovery Summit
DESCRIPTION:Bringing the covalency field under one roof for the first time\, the inaugural Covalent Drug Discovery Summit comes to Boston this December – gathering 80+ covalent drug specialists from the likes of Amgen\, Revolution Medicines\, Novartis\, Totus Medicines\, Covant Therapeutics and more. \nThis is a unique opportunity to network with an audience of CXOs\, VPs\, Directors and Heads of Discovery\, Medicinal and Biological Chemistry focused on covalent drug discovery. \nHear from 20+ industry leaders across three days of carefully curated content\, engage in dedicated networking time with the field\, ask your burning questions to our expert speakers at the end of each presentation\, and dive deep into two interactive workshops on toxicity and safety concerns and the future of covalency. \nDownload your copy of the program here to find out more: https://ter.li/z6hwj6
URL:https://www.pharmajournalist.com/event/covalent-drug-discovery-summit/
LOCATION:Hilton Boston Back Bay\, 40 Dalton St\, Boston\, MA\, 02115\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20231205
DTEND;VALUE=DATE:20231208
DTSTAMP:20260515T042055
CREATED:20230920T102331Z
LAST-MODIFIED:20230920T102331Z
UID:37817-1701734400-1701993599@www.pharmajournalist.com
SUMMARY:3rd Applied Biocatalysis Summit
DESCRIPTION:Enzyme Engineering Enabling Scalable Industrial Biotransformation for Sustainable API Production \nIn 2023\, an era of advanced enzyme engineering technology is rapidly enabling the generation of game-changing enzymes for novel transformations. As witnessed for Merck’s Islatravir and BMS’ ERED/KRED biocatalytic cascade recognition\, industries are fast transitioning towards biocatalysis to capitalize on more sustainable means of synthesis. The 3rd Applied Biocatalysis Summit is your must-attend meeting dedicated to accelerating enzyme discovery and reaction route development\, through to scaling process chemistry for industrial applications. \nWith unmissable case studies from the likes of Merck\, Amgen\, Sanofi\, Biogen\, GSK\, and Pfizer\, this is the definitive forum to benchmark and learn with this forward-thinking community who reunite once more. \nThese industry titans have collaborated to form a comprehensive\, 3-day program covering key topics including: \n\nGaining valuable insights on chemoenzymatic catalysis research\, combining heterogeneous and homogeneous catalysis and making valued functionality using biocatalysis\, in water with Bruce Lipshutz\, Professor of Chemistry\, University of California\, Santa Barbara\nLearn how new technologies are adding efficiencies to biocatalysis’ adoption\, including AI/ML approaches\, improved screening for reaction prediction & new chemistry discoveries with Merck & Pfizer\nEngage in dynamic panel discussions addressing how cross-departmental collaboration enable the faster assessment and introduction of enzymatic catalysed reactions as early as possible with AbbVie\, Biogen & Neorocrine Biosciences\n\nDon’t miss this opportunity to join trailblazers and accelerate enzyme discovery and engineering\, discover carbon footprint-reducing reactions and refine your process scaling strategies.
URL:https://www.pharmajournalist.com/event/3rd-applied-biocatalysis-summit/
LOCATION:The Study at University City\, 20 S 33rd Street\, Philadelphia\, PA\, 19104\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20231205
DTEND;VALUE=DATE:20231208
DTSTAMP:20260515T042055
CREATED:20230915T100043Z
LAST-MODIFIED:20230915T100043Z
UID:37804-1701734400-1701993599@www.pharmajournalist.com
SUMMARY:3rd ADC Target Selection Summit
DESCRIPTION:The 3rd ADC Target Selection Summit (December 5-7 | Boston\, MA). This is the ultimate cover-to-cover conference providing insights to help you optimize the pairing of target\, antibody\, and linker-payload and develop the next generation of clinically successful ADCs beyond HER2 and TROP2. \nSee the full program here. \nAs the number of new clinical ADC targets continues to increase\, this year’s meeting will have a greater focus on identifying and validating novel targets\, re-examining what makes a good target\, and delving into the use of proteomics to ensure you get the first step of drug development right. \nHere are some of the agenda highlights you cannot afford to miss: \n\nJoin Cancer Research Horizons to learn “Overcoming Hurdles in Validating Novel Targets for Clinically Applicable ADCs” and hear how an unbiased proteomics approach with patient samples was used to discover a clinically relevant ADC target for multiple myeloma\nHear from Ziel Bio on “Discovering Cell Surface Plectin: A Highly Promising Target for Multiple Solid Tumors” to understand how the hypothesized function of plectin highlights it as a good ADC target\, and learn how ZB131 can selectively bind to CSP improving internalization and minimizing off-target effects\nGain insights from AstraZeneca on “A Case Study on Utilizing Hindsight Following Progression of an ADC With a HER2 Target Into the Clinic” highlighting the target selection process and reasons behind the choice of pursuing HER2\, target and antibody considerations; and emphasizing challenges and successes in the use of this target for ADCs to help you prepare for your development.\n\nTake a look at the full speaker faculty and session details. \nUniting 100+ of your peers working in biology\, discovery and oncology research\, this unique forum will provide you with an exclusive opportunity to learn and network with other ADC developers who are living and breathing targets all in one room.
URL:https://www.pharmajournalist.com/event/3rd-adc-target-selection-summit/
LOCATION:Hilton Boston Logan Airport\, One Hotel Dr\, Boston\, MA\, 02128\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:adc@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20231128
DTEND;VALUE=DATE:20231201
DTSTAMP:20260515T042055
CREATED:20230829T091427Z
LAST-MODIFIED:20230829T091427Z
UID:37688-1701129600-1701388799@www.pharmajournalist.com
SUMMARY:Advanced Purification for Complex Biologics Summit
DESCRIPTION:The Advanced Purification for Complex Biologics Summit is the first and only standalone conference focused on purification for biologics and novel modalities bringing together purification\, CMC and MSAT professionals to collaborate and remove purification bottlenecks to meet market delivery timelines. \nThis in-depth 3-day event will feature the latest breakthroughs and cutting-edge content in AI and digital learning tools to help you save time during downstream processing and boost efficiency. \nThis is your unique opportunity to meet 60+ purification and downstream processing experts including Sanofi\, Takeda\, Eli Lilly\, AstraZeneca and Regeneron as they talk you through machine learning\, predictive modelling\, and consumables advancements to empower your process optimization\, moving a step closer to 100% product purity. \nTo know more visit: https://ter.li/80pxjz
URL:https://www.pharmajournalist.com/event/advanced-purification-for-complex-biologics-summit/
LOCATION:Sonesta Philadelphia Rittenhouse Square\, 1800 Market Street\, Philadelphia\, PA\, 19103\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20231128
DTEND;VALUE=DATE:20231201
DTSTAMP:20260515T042055
CREATED:20230825T133450Z
LAST-MODIFIED:20230825T133450Z
UID:37674-1701129600-1701388799@www.pharmajournalist.com
SUMMARY:4th Annual CRISPR 2.0 Congress 2023
DESCRIPTION:CRISPR represents the next frontier in the cell and gene therapy landscape. Spearheaded by the first gene edited therapeutic awaiting FDA approval\, a mounting wave of innovative technology developments and therapeutic applications are leading to a paradigm shift in our global healthcare systems. \nTo this end\, the 4th Annual CRISPR 2.0 Congress is your definitive guide to showcasing the latest and greatest CRISPR tools being developed and applied in the therapeutic setting. \nTo know more visit: https://ter.li/rqwuyn
URL:https://www.pharmajournalist.com/event/4th-annual-crispr-2-0-congress-2023/
LOCATION:Hilton Boston Logan Airport\, One Hotel Dr\, Boston\, MA\, 02128\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20231128
DTEND;VALUE=DATE:20231201
DTSTAMP:20260515T042055
CREATED:20230822T114102Z
LAST-MODIFIED:20230822T114159Z
UID:37658-1701129600-1701388799@www.pharmajournalist.com
SUMMARY:Donor Selection & Cell Source Summit 2023
DESCRIPTION:The Donor Selection & Cell Source Summit is your ultimate platform to explore the latest global regulatory requirements and differences on donor testing\, understand the novel genome sequencing data being used to inform donor selection\, and forge new partnerships to ease logistical coordination with donation sites to ensure exclusive availability of selected donor pools. \nJoin Senti Biosciences\, Poseida Therapeutics\, Caribou Bio\, Allogene and more to advance your knowledge on donor selection\, management and sustainability to ensure a consistent and reliable supply of cell source material required for clinical trials and beyond. \nDownload a copy of the event guide to view the 3-day jam-packed agenda\, expert speaker faculty and exclusive pre-conference workshop day: https://ter.li/t81hko
URL:https://www.pharmajournalist.com/event/donor-selection-cell-source-summit-2023/
LOCATION:The Clift Royal Sonesta\, 495 Geary Street\, San Francisco\, CA\, 94102\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20231128
DTEND;VALUE=DATE:20231201
DTSTAMP:20260515T042055
CREATED:20230724T153728Z
LAST-MODIFIED:20230724T153728Z
UID:37515-1701129600-1701388799@www.pharmajournalist.com
SUMMARY:Cell Therapy for Autoimmune Disease Summit
DESCRIPTION:Enter the inaugural Cell Therapy for Autoimmune Disease Summit\, a pioneering platform singularly focused on uniting and empowering this community for the first time. Experts will delve into cutting-edge frontiers of pre-clinical\, translational\, and clinical advancements encompassing all cell-based therapies\, including CAR-T\, Treg\, and MSC\, with the shared objective of developing better therapies for patients with chronic autoimmune diseases. \nDon’t miss out on your opportunity to network with 80+ key opinion leaders including Cabaletta Bio\, Kyverna Therapeutics\, AstraZeneca\, Quell Therapeutics\, Novartis\, and more. Learn more – https://ter.li/6xwjrk
URL:https://www.pharmajournalist.com/event/cell-therapy-for-autoimmune-disease-summit/
LOCATION:Sonesta Philadelphia Rittenhouse Square\, 1800 Market Street\, Philadelphia\, PA\, 19103\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20231127
DTEND;VALUE=DATE:20231130
DTSTAMP:20260515T042055
CREATED:20230925T125234Z
LAST-MODIFIED:20230925T125234Z
UID:37847-1701043200-1701302399@www.pharmajournalist.com
SUMMARY:7th Obesity & NASH Drug Development Summit
DESCRIPTION:Eli Lilly’s ‘triple G’ drug retatrutide has galvanized the metabolic field to boost investment in the game-changing obesity drug revolution. With up to 24% weight loss\, a new record for the obesity field has been set and the time to get ahead of the curve is now. In parallel\, we’re witnessing history being made with the world’s first approved NASH treatment potentially being right around the corner with Madrigal’s THR β-selective agonist\, marking this year a pivotal time for the metabolic field to forever elevate the approach towards drug development and overcome regulatory barriers. \nReuniting metabolic experts to enable the assessment of the competitive landscape\, the 7th Obesity & NASH Drug Development Summit is uniquely positioned to capture all the latest breakthroughs and research you need to join the race and commercialize your GLP-1 RAs\, tri-agonists\, dual agonists\, tetra-specific drugs\, glucocorticoid receptor modulators and more. \n2023 is an exciting year due to the evolution in digital pathology\, artificial intelligence\, omics\, multifunctional molecules\, non-invasive biomarkers\, target discovery and liver models\, this is your timely meeting dedicated to bringing the metabolic community closer to navigate the route to even more approvals. However\, as industry gets closer to successes\, challenges remain. \nKeen to overcome these discovery\, regulatory\, clinical\, and commercial hurdles? \nJoin 160+ experts at the largest gathering of obesity and NASH industry drug developers from Eli Lilly\, Novo Nordisk\, Madrigal\, Akero\, Gilead\, Pfizer\, AstraZeneca\, Gilead\, Inventiva and many more to cultivate sustainable weight-loss drugs and navigate the route towards the first approval in NASH. Don’t miss your opportunity to hear from 42+ metabolic experts over 3 jam-packed days with all the latest end-to-end updates to advance your drug development. \nTo know more visit: https://bit.ly/465Aa3m
URL:https://www.pharmajournalist.com/event/7th-obesity-nash-drug-development-summit/
LOCATION:The Westin Boston Seaport District\, 425 Summer Street\, Boston\, MA\, 02210\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20231127
DTEND;VALUE=DATE:20231201
DTSTAMP:20260515T042055
CREATED:20230803T103428Z
LAST-MODIFIED:20230803T103428Z
UID:37560-1701043200-1701388799@www.pharmajournalist.com
SUMMARY:5th Annual Gene Therapy Analytical Development Summit 2023
DESCRIPTION:Behind regulatory milestones like the recent accelerated FDA approval for Duchenne Muscular Dystrophy\, robust and detailed analytics are the cornerstone of gene therapy development. As regulators scrutinize products more closely\, accurately characterizing gene therapy products and standing behind safety and efficacy is crucial to drug developers bringing gene therapies into and through the clinic. \nIn this context\, the 5th Annual Gene Therapy Analytical Development is returning in 2023\, uniting 400+ analytical experts to explore how the latest analytical methods are being developed and applied to guarantee the quality\, consistency\, safety\, and efficacy of gene therapy products. \nJoin biopharma colleagues specializing in bioassays\, molecular biology\, physicochemical properties\, quality\, process development and regulation across 4 days of niche\, expert presentations\, and dedicated networking opportunities. This is your must-attend meeting to collaborate ideas\, success and challenges to capitalize on the technological advances in analytical development to reach the ultimate goal of bringing safer\, efficacious therapies to patients more quickly and effectively. \nTo know more visit: https://ter.li/qf50s3
URL:https://www.pharmajournalist.com/event/5th-annual-gene-therapy-analytical-development-summit-2023/
LOCATION:Boston Park Plaza\, 50 Park Plaza\, Boston\, MA\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20231107
DTEND;VALUE=DATE:20231110
DTSTAMP:20260515T042055
CREATED:20231002T095350Z
LAST-MODIFIED:20231002T095350Z
UID:37885-1699315200-1699574399@www.pharmajournalist.com
SUMMARY:7th Microbiome Movement – Human Nutrition Summit
DESCRIPTION:The 7th Microbiome Movement – Human Nutrition Summit will unite 100+ human nutrition leaders this November in Livingston\, NJ to optimize product development and consumer acceptance of microbiome-based food and nutritional products. Join the only industry led meeting dedicated to moving the needle on scientifically validated\, microbiome modulating\, nutritional product development. \nFrom developing pre-\, pro-\, or post-biotics\, functional food\, microbiome modulating ingredients\, to other interventions that provide microbial-mediated health benefits\, this meeting offers unrivalled opportunities for those working in the microbiome human nutrition space. \nJoin us in Livingston\, NJ\, this November to hear invaluable insights from the likes of Bifidice\, Danone\, Holobiome\, ADM\, Immune Biome\, and more! \nView the full event guide here: https://ter.li/2ppxtz \nOffering earlybird rates\, exclusive group discounts and a brand-new\, post-conference consumer focus day\, now is the time to register. Don’t miss out\, secure your place now: https://ter.li/8algsb
URL:https://www.pharmajournalist.com/event/7th-microbiome-movement-human-nutrition-summit/
LOCATION:Westminster Hotel\, 550 W Mt Pleasant Ave\, Livingston\, NJ\, 07039\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20231107
DTEND;VALUE=DATE:20231108
DTSTAMP:20260515T042055
CREATED:20230829T092031Z
LAST-MODIFIED:20230829T092031Z
UID:37692-1699315200-1699401599@www.pharmajournalist.com
SUMMARY:PURIFY’23
DESCRIPTION:PURIFY – Chromatography Purification Conclave \nPURIFY Conclaves are pioneers of dedicated conferences in India that will help stretch possibilities\, be it discovery\, development or scaleups! \nThe pharmaceutical industry continues to dwell deeper into the growing possibilities for chromatography purification; the PURIFY conclaves touches upon diverse aspects of chromatography purification. \nThe attendees at PURIFY get exposed to a myriad of topics that could change the way they work…change the way they purify. New separation techniques and approaches\, niche topics\, deeper understanding of preparative and process chromatography and allied fields\, and upcoming application areas that will provide quality substance to the discerning scientists. So\, if you wish to get that additional gram\, which is purer\, in as less a time\, with minimal resources…there will surely be something for you at PURIFY conclaves! \nThe annually occurring PURIFY Conclave is an initiative by Custage Marketing Solutions LLP\, a Mumbai based company. \nThe PURIFY conclave is attended by analytical and research chemists\, scientists with scale-up and process development knowledge\, managers\, group heads\, natural product purification experts\, experts from quality and manufacturing\, academicians\, policy makers\, supply chain heads etc. of this pharmaceutical – APIs\, peptides\, proteins\, oligonucleotides\, chiral molecules\, bio-pharmaceutical\, fine chemicals\, environmental studies\, food and beverage\, polymers\, biotechnology\, cosmetics and fragrance to understand the advancements in chromatography platforms. \nSo\, the purification expert in you will surely get answers to the daily challenges faced for you in your laboratories. And what’s more\, the knowledge comes to you from dignitaries who are institutions on their own in chromatography purification and related. \nTo know more visit: https://www.purifyconclaves.com/
URL:https://www.pharmajournalist.com/event/purify23/
LOCATION:ITC KOHENUR\, HYDERABAD\, INDIA
ORGANIZER;CN="Custage Marketing Solutions LLP":MAILTO:rashi@custage.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20231106
DTEND;VALUE=DATE:20231108
DTSTAMP:20260515T042055
CREATED:20230912T141209Z
LAST-MODIFIED:20230912T141209Z
UID:37773-1699228800-1699401599@www.pharmajournalist.com
SUMMARY:Extractables & Leachables Europe 2023
DESCRIPTION:Join us at this year’s much-anticipated Extractables and Leachables Europe\, taking place on 6-7 November 2023 in Amsterdam. \nThis year’s conference promises to once again provide you with everything you need to know about this ever-evolving sector. Extractables and leachables examination is continuously growing in importance. Given the current scrutiny paid by governing bodies including the FDA and MHRA\, understanding the best practice and guidelines to carry out extractables and leachables studies is imperative in order to eliminate risk and potential development delays. \nWhatever your level or position\, and whether you’re from a CRO\, pharmaceutical manufacturer\, packaging specialist\, instrument or equipment manufacturer\, research or academic institution\, chemical company or OEM – this conference has something for everyone. \nWith speakers from reputable companies like Element\, GSK Vaccines\, Aptar Pharma\, Octapharma\, Sartorius Stedim Biotech and numerous others\, the agenda is bursting with insights\, helping the conference be the most exceptional one to date. \nDescribed by a previous attendee as ‘the place to be for the E&L community’\, this is a mist-attend event for anyone working in the industry. \nFind out more here: https://www.eandl-conference.com/extractables-and-leachables-europe \nIn addition to organising the renowned E&L events in Europe\, US and China\, Smithers also have a long history in providing E&L and medical device testing across the globe. Find out more at www.smithers.com.
URL:https://www.pharmajournalist.com/event/extractables-leachables-europe-2023/
LOCATION:Steinberger Airport Hotel\, Stationsplein Zuid-West 951\, 1117 CE Schiphol\, Netherlands\, 1117 CE\, Netherlands
ORGANIZER;CN="Smithers":MAILTO:pregnault@smithers.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20231106
DTEND;VALUE=DATE:20231110
DTSTAMP:20260515T042055
CREATED:20230628T105940Z
LAST-MODIFIED:20230628T105940Z
UID:37371-1699228800-1699574399@www.pharmajournalist.com
SUMMARY:5th Gene Therapy for Neurological Disorders Summit
DESCRIPTION:Accelerating More Transformative Gene Therapies for CNS Disorders \nDespite a challenging 2022 for Gene Therapy developers targeting the CNS\, the recent approvals of Skysona by bluebird bio and Upstaza by PTC Therapeutics have validated the potential that gene therapies can act as transformative medicines within the CNS community. \nThe 5th Gene Therapy for Neurological Disorders Summit is your comprehensive 4-day event to stay ahead of cutting-edge developments\, overcome delivery challenges\, address translational bottlenecks\, and create a bulletproof clinical development strategy\, to propel the next wave of CNS gene therapies forward. \nThis summit will unite 200+ gene therapy and neurology leaders with a program designed to cater to everyone from Discovery through to Clinical Development; this is your only opportunity for a cover-to-cover discussion full of need-to-know and practical insights. \nNow that the neurological gene therapy field has been given a renewed sense of direction\, this is the opportunity for the community to capitalize on the start of a new wave of innovation and optimize the potential for gene therapies targeting neurological disorders. \nTo know more visit: https://ter.li/iblyl1
URL:https://www.pharmajournalist.com/event/5th-gene-therapy-for-neurological-disorders-summit/
LOCATION:Boston Park Plaza\, 50 Park Plaza\, Boston\, MA\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20231030
DTEND;VALUE=DATE:20231102
DTSTAMP:20260515T042055
CREATED:20230803T103923Z
LAST-MODIFIED:20230803T103923Z
UID:37564-1698624000-1698883199@www.pharmajournalist.com
SUMMARY:CRISPR-Based Therapy Analytical Development Summit
DESCRIPTION:CRISPR-based therapies are undergoing a remarkable evolution\, with drug developers striving to enhance the safety\, precision and efficacy of their products. As this paradigm takes place\, more complex CRISPR structures necessitate cutting-edge advancements in analytical methods and tools to effectively characterize the genome-edited products utilizing CRISPR technology. \nAs industry experts tread unchartered territory\, the inaugural CRISPR-Based Therapy Analytical Development Summit has been convened\, gathering more than 60 distinguished experts in analytical development devoted to the creation\, refinements and implementation of more robust analytical tools specifically tailored to CRISPR-based constructs. \nWithin this intimate space\, we will adopt a shared consensus and delve into a comprehensive array of analytical techniques central to any CRISPR-based toolkit. Topics of discussion will span pioneering technology that includes everything from novel methods to characterize the guide RNA and whole CRISPR complex\, to the use of next-generation sequencing (NGS) to detect and assess off-targets for superior safety evaluations. \nIn response to the regulatory bodies’ insistence on high-quality data to substantiate the safety and efficacy of genome-edited products\, this summit is imperative to all individual engaged in the development of analytical tools and methodologies utilizing CRISPR technology as we build for better guidance around CRISPR-edited products. \nIf your role centers around analytical expertise and gene edited specialization\, this meeting will enable you to streamline your analytical development process and connect in a shared goal to deliver safer therapies\, with superior therapeutic benefit to patients faster. \nTo know more visit: https://ter.li/28jg6x
URL:https://www.pharmajournalist.com/event/crispr-based-therapy-analytical-development-summit/
LOCATION:Hilton Boston Bay Back\, 40 Dalton St\, Boston\, MA\, 02115\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20231023
DTEND;VALUE=DATE:20231025
DTSTAMP:20260515T042055
CREATED:20230810T114239Z
LAST-MODIFIED:20230810T114239Z
UID:37598-1698019200-1698191999@www.pharmajournalist.com
SUMMARY:Biosensors for Medical Wearables Conference and Expo
DESCRIPTION:Biosensors for Medical Wearables Conference and Expo  \n*In collaboration with Medical Design Briefs* \nOctober 23-24\, 2023 | Boston\, MA\, USA \nhttp://www.biosensors-medical-wear.com/PharmaJournalist-WL \nSAE Media Group’s 3rd Annual Biosensors for Medical Wearables Conference will be back for 2023 in Boston to bring together device developers\, MedTech\, component manufacturers and big pharma to share and discuss the exciting advances in the medical wearable technology landscape. \nThe wearable biosensors market has grown significantly in recent years leading to increasingly growing potential for medical applications and at home alternatives for patients. With growing applications and potential in remote patient monitoring\, diagnosis\, therapeutics and detection of disease\, wearable sensors are attracting considerable interest due to their opportunities in better supporting patients\, clinical outcomes and decisions. Furthermore\, AI and connected technologies are furthering the potential opportunities of this industry. However\, challenges including flexibility of wearable devices\, the collection of clinical-grade data and advanced battery technologies still remain for the industry to overcome. This year’s conference looks to address these hot topics through case studies and industry insights. \nThis is a must attend event\, giving you the chance to engage in the latest innovations that are accelerating the wearable biosensors industry. We hope to welcome you in October 2023! \nReasons to attend: \n\nBenchmark against and explore the latest biosensor technologies for wearable medical devices from Abbott\, Empatica and Hexoskin\nDelve into the potential of wearable sensors and digital tools in decentralized diagnosis including a Johnson & Johnson case study on the Heartline project\nLearn how game changing companies such as Philips and Medtronic are utilizing wearables to maximize remote patient monitoring opportunities for wider patient populations\nExplore how AI and machine learning technologies are enabling optimized data collection and streamlined data analysis\nDiscover cutting-edge biosensor therapeutic applications for neurology with Neurasantys and a panel discussion on future medical opportunities\n\nWho you can meet? \n\nAndreas Caduff\, Strategic Advisory Board\, DiME\nLorelie Villarete\, Manager\, Clinical Affairs\, Lingo Sensing Technology Unlimited Company (an Abbott Company)\nTim Callahan\, VP Scientific Affairs\, Philips\nKara Chappie\, Director and Project Lead\, Pfizer\nJason Case\, Vice President\, Research and Development\, Patient Monitoring\, Medtronic\nJames Mault\, MD\, Founder and CEO\, BioIntellisense\, Inc.\nJasmin Imsirovic\, Associate Director\, Takeda\nJanet Nikolovski\, New Venture Lead – Genitourinary Oncology\, Johnson & Johnson
URL:https://www.pharmajournalist.com/event/biosensors-for-medical-wearables-conference-and-expo/
LOCATION:COURTYARD BY MARRIOTT BOSTON DOWNTOWN\, 275 Tremont St\, Boston\, MA\, 02116\, United States
ORGANIZER;CN="SAE MEDIA GROUP":MAILTO:events@saemediagroup.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20231023
DTEND;VALUE=DATE:20231026
DTSTAMP:20260515T042055
CREATED:20230628T104642Z
LAST-MODIFIED:20230628T104642Z
UID:37361-1698019200-1698278399@www.pharmajournalist.com
SUMMARY:11th IMPACCT: Real World Evidence Summit 2023
DESCRIPTION:Returning for its 11th year\, the IMPACCT: Real World Evidence Summit 2023 will deep dive into the use of RWE for regulatory submissions and clinical trial innovation to unlock unstructured healthcare data and transform disease treatment. \nJoin 100+ senior leaders in RWE\, RWD\, real world analytics & epidemiologists from pharma and biotech to take part in this three-day summit with over 18 hours of exclusive content. \nDon’t miss your unique opportunity to explore how to leverage RWE to target patient populations and drive DE&I into trials. For more information go to: https://ter.li/db1xte
URL:https://www.pharmajournalist.com/event/11th-impacct-real-world-evidence-summit-2023/
LOCATION:Hilton Boston Logan Airport\, One Hotel Dr\, Boston\, MA\, 02128\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20231017
DTEND;VALUE=DATE:20231020
DTSTAMP:20260515T042055
CREATED:20230724T153358Z
LAST-MODIFIED:20230724T153358Z
UID:37509-1697500800-1697759999@www.pharmajournalist.com
SUMMARY:2nd Innate Killer Summit Europe 2023
DESCRIPTION:The 2nd Innate Killer Europe Summit will gather 80+ key European Gamma Delta T\, NK\, iNKT\, neutrophil\, and macrophage developers in October to chase the holy grail of efficacious\, off-the-shelf\, solid tumour immunotherapies through effective and scalable engineering\, engager and combination strategies that promote safe\, potent and persistent innate immune therapies following application. \nDon’t miss this chance to network with innate immune trailblazers from the likes of Sanofi\, Takeda\, Lift Biosciences\, Mink Therapeutics\, Affimed\, Carisma Therapeutics\, Arovella Therapeutics and receive 3-days of some of the best scientific and data driven case studies that will help propel your innate immune therapy into the clinic and beyond. Learn more – https://ter.li/nkcwg3
URL:https://www.pharmajournalist.com/event/2nd-innate-killer-summit-europe-2023/
LOCATION:Crowne Plaza London\, Royal Victoria Dock\, Western Gateway\, London\, E16 1AL\, United Kingdom
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20231016
DTEND;VALUE=DATE:20231019
DTSTAMP:20260515T042055
CREATED:20230831T083951Z
LAST-MODIFIED:20230905T090233Z
UID:37702-1697414400-1697673599@www.pharmajournalist.com
SUMMARY:4th Commercializing Flow Chemistry Summit
DESCRIPTION:Scaling Flow Chemistry for Sustainability\, Safety and Speed to Market  \nWith the growing demand for better flow technology\, the 4th Commercializing Flow Chemistry Summit is your must-attend meeting to deep-dive into transforming your process efficiency\, emerging technology toolbox and economic gains through strategic flow chemistry. \nWith unmissable case studies from the likes of Novartis\, Boehringer Ingelheim\, Sanofi\, AbbVie\, Eli Lilly and Takeda\, this is the definitive forum to benchmark and learn with this forward-thinking community who reunite once more. \nThese industry titans have collaborated to form a comprehensive\, 3-day program covering key topics including: \n\nElevate Sustainability with Industry Leaders: Join forces with Merck\, Eli Lilly and AbbVie to integrate sustainable practices seamlessly into your workflow\, enhancing both environmental responsibility and operational excellence\nUnlock Efficiency through Automation: Discover the power of automation in flow chemistry\, following the footsteps of efficiency leaders like Sanofi\, Takeda\, and Boehringer Ingelheim\, and optimize your processes for peak performance\nMaster Multi-Step Techniques: Gain expert insights from Boehringer Ingelheim on handling multi-step reactions in both flow and batch setups\, fine-tuning your manufacturing processes for maximum efficiency and output\n\nDon’t miss this opportunity to streamline your continuous chemistry research into scaled commercial applications\, and together with 80+ process chemists\, engineers\, and modellers\, go beyond reaction to work up optimization to develop winning processes quicker and expedite your drug development. \nTo know more visit: https://ter.li/jfxs1m
URL:https://www.pharmajournalist.com/event/4th-commercializing-flow-chemistry-summit/
LOCATION:Hilton Boston Back Bay\, 40 Dalton St\, Boston\, MA\, 02115\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20231016
DTEND;VALUE=DATE:20231019
DTSTAMP:20260515T042055
CREATED:20230718T090856Z
LAST-MODIFIED:20230718T090856Z
UID:37484-1697414400-1697673599@www.pharmajournalist.com
SUMMARY:2nd Operationalise: Early Access Programmes Europe Summit
DESCRIPTION:The Early Access Programmes Summit Europe returns for a second year this October\, aiming to help the industry navigate the notoriously complex European regulatory landscape\, and conquer operational hurdles to provide patients in Europe with early access to medicines. \n \nThis meeting provides a forum to address burning questions and share ideas on topics such as European regulatory guidelines\, labelling\, supply\, and best practices around reimbursement\, integrating of pre- and post-trial access programmes and scoping. \nProviding practical\, valuable case studies is this year’s expert speaker lineup including the likes of GlaxoSmithKline\, Roche\, Novartis\, Sanofi\, and many others! Visit our website to download a free copy of the full event guide to explore the jam-packed 3-day agenda and full speaker faculty. \nWhether you’re a veteran at managing early access programmes and are looking to expand your geo\, or a new entrant to the field\, you’ll leave this conference with the practical lessons and essential connections needed to supercharge your European early access programme across 2023 and beyond. \nTo know more visit: https://bit.ly/3K4BpqO
URL:https://www.pharmajournalist.com/event/2nd-operationalise-early-access-programmes-europe-summit/
LOCATION:Hilton Canary Wharf\, South Quay\, Marsh Wall\, London\, E14 9SH\, United Kingdom
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20231016
DTEND;VALUE=DATE:20231020
DTSTAMP:20260515T042055
CREATED:20230524T141827Z
LAST-MODIFIED:20230524T141827Z
UID:37236-1697414400-1697759999@www.pharmajournalist.com
SUMMARY:14th World ADC San Diego 2023
DESCRIPTION:The ADC renaissance shows no sign of slowing down with the ground-breaking approval of ELAHERE for platinum resistant ovarian cancer\, Pfizer’s jaw-dropping acquisition of Seagen for $43 billion\, and BMS’ $1 billion+ pact with Tubulis. There has been no better time to reunite the World ADC community and invest in progressing ADCs to front line treatments for patients. \nThe highly anticipated 14th World ADC San Diego (October 16-19\, 2023 | San Diego\, CA) returns as the world’s largest industry-dedicated discussion and networking forum addressing and overcoming the challenges in end-to-end ADC development. \nGain exclusive access to the full event guide to view the full agenda with 120+ industry-leading speakers. \nWhether you’re new to the field or an ADC guru\, there is something for everyone included in this year’s agenda. Some of your must-attend talks per track include: \n\nDiscovery Chemistry: Join Christopher Marvin\, Principal Research Scientist\, AbbVie as he reviews the design and optimization of glucocorticoid receptor modulator payloads for Immunology ADCs\nCellular Biology: Discuss with Robert Lawrence\, Principal Scientist\, Seagen the influence of artificial intelligence on ADC target discovery\nTranslational: Review a best-in-class translational study with Meijuan Li\, Vice President\, Head of Translational Sciences & Biostatistics\, Eisai Oncology\nClinical Lessons: Be the first to hear industry-changing clinical results from ImmunoGen\, Byondis\, Iksuda Therapeutics\, Seagen\, Bliss Bio\, Genentech and Elucidia Oncology\nProcess and Analytical Development: Debate the key considerations for ADC comparability studies in a dedicated roundtable lead by ADC CMC expert\, Julie Beaudet\, CMC Staff Scientist\, Regeneron Pharmaceuticals\nManufacturing and Supply Chain: Explore the manufacturing of novel dolaLock ADCs with supply chain architecture with Engin Ayturk\, Executive Director\, CMC Process Development\, Mersana Therapeutics\n\nAccess to the complete agenda here including a 7-tracked seminar day and 10 industry-beating workshops. \nDon’t miss out on the chance to reunite with the antibody-drug conjugate community while reflecting on the exciting year that ADCs have had\, and building momentum for the future of this innovative field.
URL:https://www.pharmajournalist.com/event/14th-world-adc-san-diego-2023/
LOCATION:Sheraton San Diego Hotel and Marina\, 1380 Harbor Island Dr\, San Diego\, CA\, 92101\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20231010
DTEND;VALUE=DATE:20231013
DTSTAMP:20260515T042055
CREATED:20230628T105645Z
LAST-MODIFIED:20230628T105645Z
UID:37366-1696896000-1697155199@www.pharmajournalist.com
SUMMARY:6th Neuropsychiatric Drug Development Summit
DESCRIPTION:The Definitive Industry Forum for Spearheading Non-Psychedelic & Psychedelic R&D \n2023 is booming with novel psychiatric R&D and the promise of precision medicine for neuropsychiatric patients. Pipelines are gaining momentum\, with notable approvals on the horizon\, as unmet needs in PTSD\, bipolar\, anxiety\, schizophrenia\, depression\, and ADHD become greater and greater. There is\, therefore\, a huge deal of novel and promising research to be discussed this October at the 6th Neuropsychiatric Drug Development Summit. \nWith discovery\, preclinical\, translational\, and clinical scientists from the likes of Biogen\, Otsuka\, AbbVie\, Genentech\, Lundbeck\, Delix Therapeutics\, Atai\, Gilgamesh\, and Cerevel Therapeutics\, don’t miss the field’s favorite conference\, specifically dedicated to biopharma’s most pressing challenges of de-risking the translational gap and advancing transformative neuropsychiatric candidates through the clinic. \nTo know more visit: https://ter.li/sar413
URL:https://www.pharmajournalist.com/event/6th-neuropsychiatric-drug-development-summit/
LOCATION:Hilton Boston Back Bay\, 40 Dalton St\, Boston\, MA\, 02115\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20231009
DTEND;VALUE=DATE:20231011
DTSTAMP:20260515T042055
CREATED:20230810T115308Z
LAST-MODIFIED:20230810T115430Z
UID:37608-1696809600-1696982399@www.pharmajournalist.com
SUMMARY:Wearable Injectors and Connected Devices Conference & Expo
DESCRIPTION:Wearable Injectors and Connected Devices Conference & Expo \n9 – 10 October 2023 | London\, UK \nhttp://www.wearable-injectors.co.uk/PharmaJournalist-EL \nStrategies to advance digital health and on-body drug devices for large volume delivery \nSAE Media Group are proud to announce the 4th annual Wearable Injectors and Connected Devices conference. As the need for at home self-administration and routes for delivery of time-dependent and high-volume drug delivery grows\, on-body injectors and connected devices hold great opportunity. \nThe conference will delve into on-body device design and development\, enhancing digital connectivity for injectable devices\, strategic approaches to wearable device design\, regulatory considerations and primary container considerations for large volume delivery systems. \nAs part of SAE Media Group’s leading Injectable series of conferences\, we bring together high-level experts from big pharma and device developers to network and share knowledge to advance R&D. The two-day conference will not only bring you high-quality key insights needed to enhance your wearable devices and connected product portfolio but will also give you the opportunity to network with key players throughout the industry. We hope to welcome you to this must attend event in October 2023! \nBenefits of Attending: \n\nEngage with key regulatory updates surrounding digital health and medical devices\nDiscover advances in device design and development for large volume delivery via on-body injectors\nExplore the key drivers of novel drug products for the development for on-body injectors\nHear insights into the growing potential of digital health to improve patient experience and treatment\nDevelop your understanding of design strategies for connectivity and digital health\n\nDelegates will have the opportunity to network with the following companies: \n\nJohnson & Johnson\nBiogen\nAstraZeneca\nMerck KGaA\nNovartis\nNovo Nordisk\nBoehringer Ingelheim\n\nAnd many more!! \nWho Should Attend: \n\nExecutives\, Directors\, VPs\, Heads\, Principals\, Managers of:\nDrug-Delivery Developers\nAutoinjectors\nDevice Engineering\nHuman Factors\nInjectables\nPackaging\nRegulatory Affairs\nConnectivity\nMedical Device Data\nNovel Product Technology\nSmart Device Developers\nDevice Safety Solution Providers\nor anyone who works with Wearable Devices/ On-Body Injectors within pharmaceuticals\, biotech\, device developers and solution providers.\n\nThe two-day conference will bring you high-quality insights and industry connections on the latest advances in wearable injectors and connectivity\, and a platform for exchanging ideas.
URL:https://www.pharmajournalist.com/event/wearable-injectors-and-connected-devices-conference-expo/
LOCATION:Hilton London Kensington\, 179-199 Holland Park Ave\, London\, W11 4UL\, United Kingdom
ORGANIZER;CN="SAE MEDIA GROUP":MAILTO:events@saemediagroup.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20231002
DTEND;VALUE=DATE:20231005
DTSTAMP:20260515T042055
CREATED:20230608T110740Z
LAST-MODIFIED:20230608T110740Z
UID:37302-1696204800-1696463999@www.pharmajournalist.com
SUMMARY:5th TIL Therapies Summit
DESCRIPTION:With the first commercial TIL therapy brewing at Iovance\, along with various clinical readouts which are set to come to fruition in 2023\, the race is on for the next generation of modified TIL to enter the clinic. \n \nReturning as the only forum to address bottlenecks in end-to-end TIL development\, the 5th TIL Therapies Summit is designed exclusively for TIL experts to fast-track your program into the clinic and beyond. \nUnite with this niche community across industry and academia as pioneers from Iovance Biotherapeutics\, Turnstone Biologics\, Achilles Therapeutics and Lyell Immunopharma share clinical updates\, next-gen engineering\, and novel innovations to turbocharge preclinical and clinical development of safe\, scalable and effective TIL therapies. \nWith 23+ expert speakers\, 8 new companies and a brand-new Manufacturing & Characterization Bootcamp\, you won’t want to miss this unrivalled opportunity to connect and collaborate with industry leaders. \nDon’t let your team get left behind! Join us as we accelerate the next wave of TIL therapies into the clinic and beyond. Find out more – https://ter.li/mk23q3.
URL:https://www.pharmajournalist.com/event/5th-til-therapies-summit/
LOCATION:Hilton Boston Logan Airport\, One Hotel Dr\, Boston\, MA\, 02128\, United States
ORGANIZER;CN="Hanson Wade Group":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230926
DTEND;VALUE=DATE:20230929
DTSTAMP:20260515T042055
CREATED:20230704T142733Z
LAST-MODIFIED:20230704T142733Z
UID:37413-1695686400-1695945599@www.pharmajournalist.com
SUMMARY:2nd mRNA Process Development & Manufacturing Summit
DESCRIPTION:Returning to Boston as the world’s only industry-leading meeting focused on mRNA process development and manufacturing\, join 200+ VPs\, Directors and Heads of Process Development\, MSAT\, Technical Operations\, CMC and more from large pharma\, innovative biotechs\, and academia. \nDownload the program here: https://ter.li/5o4hdl \nThis must-attend meeting will provide you with technical insight and know-how from the largest process development and manufacturing speaker faculty to date\, enabling you to revolutionize your processes for effective industrialization. \nSpanning three tracks dedicated to Research Scale\, IND-Enabling & Clinical Scale\, and Commercial Scale\, this year’s meeting will dive deep into the challenges\, requirements\, innovations and opportunities to improve your design\, development and scale-up solutions from drug substance to drug product for regulatory and market readiness. \nRegister here: https://ter.li/nu15iq
URL:https://www.pharmajournalist.com/event/2nd-mrna-process-development-manufacturing-summit/
LOCATION:Boston Convention and Exhibition Center (BCEC)\, 415 Summer Street\, Boston\, MA\, MA 02210\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
END:VCALENDAR